Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics

Página do item simplificado
dc.contributor.authorOrofino-Costa, Rosane
dc.contributor.authorde Macedo, Priscila Marques
dc.contributor.authorRodrigues, Anderson Messias [UNIFESP]
dc.contributor.authorBernardes-Engemann, Andrea Reis
dc.date.accessioned2019-08-19T11:48:22Z
dc.date.available2019-08-19T11:48:22Z
dc.date.issued2017
dc.description.abstractIn the late 90' s there was a change in both the route of transmission and the people at risk for sporotrichosis. This zoonotic cat-man alternative transmission route elicited changes in strategies to control the epidemic. There was a progressive increase in the number of cases involving especially children and the elderly. In addition to becoming hyperendemic, uncommon clinical pictures like immunoreactive clinical presentations or severe systemic cases have emerged. New species were identified and classified through molecular tools using more virulent clinical isolates, like S. brasiliensis, compared to the environmental isolates. Likewise, different species of Sporothrix have been associated with different geographic regions. The serological and molecular techniques are used as an auxiliary tool for the diagnosis and/or for species identification, although the isolation and the identification of Sporothrix spp. in clinical specimen is still the gold standard. Currently sporotrichosis epidemics requires the knowledge of the epidemiological-molecular profile to control the disease and the specific treatment. Itraconazole, potassium iodide, terfinafine, and amphotericin B are the available drugs in Brazil to treat sporotrichosis. The drug of choice, its posology, and treatment duration vary according to the clinical presentation, the Sporothrix species, and host immune status. New treatment choices, including a vaccine, are being developeden
dc.description.abstractnevertheless, more clinical trials are required to confirm its efficacy.en
dc.description.affiliationUniv Estado Rio De Janeiro, FCM, Dermatol Dept, Rio De Janeiro, RJ, Brazil
dc.description.affiliationFundação Oswaldo Cruz INI Fiocruz, Infect Dermatol Clin Res Lab, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil
dc.description.affiliationUniv Fed São Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Lab Emerging Fungal Pathogen, São Paulo, SP, Brazil
dc.description.affiliationHosp Univ Pedro Ernesto, Med Mycol Lab, Dermatol Dept, Rio De Janeiro, RJ, Brazil
dc.description.affiliationUnifespUniv Fed São Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Lab Emerging Fungal Pathogen, São Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.format.extent606-618
dc.identifierhttp://dx.doi.org/10.1590/abd1806-4841.2017279
dc.identifier.citationAnais Brasileiros De Dermatologia. Rio De Janeiro Rj, v. 92, n. 5, p. 606-618, 2017.
dc.identifier.doi10.1590/abd1806-4841.2017279
dc.identifier.fileWOS000416001300001.pdf
dc.identifier.issn0365-0596
dc.identifier.scieloS0365-05962017000500606
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/51239
dc.identifier.wosWOS:000416001300001
dc.language.isoeng
dc.publisherSoc Brasileira Dermatologia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiagnosisen
dc.subjectEpidemiologyen
dc.subjectMolecular biologyen
dc.subjectSerologyen
dc.subjectSporothrixen
dc.subjectTherapeuticsen
dc.titleSporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeuticsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000416001300001.pdf
Tamanho:
3.39 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos